Acta Med. 2007, 50: 207-212

Phenotype Analysis of Tumour-infiltrating Lymphocytes and Lymphocytes in Peripheral Blood in Patients with Renal Carcinoma

Otakar Kopeckýa,b, Šárka Lukešováa,b, Vladimíra Vroblovác, Doris Vokurkovác, Petr Morávekd, Hynek Šafránekd, Dagmar Hlávkovác, Petr Součekc

aCharles University in Prague, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Oncological Department of District Hospital, Náchod, Czech Republic
bCharles University in Prague, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, 2nd Department of Internal Medicine, Division of Haematology, Hradec Králové, Czech Republic
cCharles University in Prague, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Department of Clinical Immunology and Allergology, Hradec Králové, Czech Republic
dCharles University in Prague, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Department of Urology, Hradec Králové, Czech Republic

Received September 1, 2006
Accepted July 1, 2007


1. Bayer, A.L., Baliga, P., Woodward, J.E.: Differential effects of transferrin receptor blockade on cellular mechanisms involved in graft rejection. Transplant. Immunol., 1999; 7:131. <>
2. Bayer, A.L., Baliga, P., Woodward, J.E.: Transferrin receptor in T cell activation and transplantation. J. Leukocyte Biol., 1998; 64:19. <>
3. Bilik, R., Mor, C., Hazaz, B., Moroz, C.: Characterisation of T lymphocyte populations infiltrating primary breast cancer. Cancer Immunol. Immunother. 1989; 28:143–7. <>
4. Böhm, M., Ittenson, A., Schierbaum, K.F., et al.: Pretreatment with interleukin-2 modulates peri-operative immuno-dysfunction in patients with renal cell carcinoma. Eur. Urol. 2002; 41:458–68. <>
5. Bremers, A.J.A., Parmiani, G.: Immunology and immunotherapy of human cancer: present concepts and clinical developments. Crit. Rev. Oncol. Hematol. 2000; 34:1–25. <>
6. Chadburn, A., Inghirami, g., Knowels, D.M.: The kinetics and temporal expression of T cell activation-associated antigens CD15 (LeuM1), CD30 (Ki-1) EMA and CD11c (LeuM5) by benign activated T cells. Hematol. Pathol. 1992; 6:193.
7. Chakraborty, N.G., Sporn, J.R., Pasquale, D.R., et al.: Suppression of lymphokine-activated killer cell generation by tumor-infiltrating lymphocytes. Clin. Immunol. Immunopathol. 1991; 59:407–16. <>
8. Characiejus, D., Pašukoniené, V., Kazlauskaité, N., et al.: Predictive value of CD8highCD57+ lymphocyte subset in interferon therapy of patients with renal cell carcinoma. Anticancer Research 2002; 22:3679–84.
9. Coventry, B.J., Weeks, S.C., Heckford, S.E., et al.: Lack of IL-2 cytokine expression despite IL-2 messenger RNA transcription in tumor-infiltrating lymphocytes in primary human breast carcinoma: selective expression of early activation markers. J. Immunol. 1996; 156:3486.
10. Donskov, F., Bennedsgaard, K.M., von der Maase, H., et al.: Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival. Br. J. Cancer 2002; 87:194–201. <> <PubMed>
11. Elsässer-Beile, U., Gierschner, D., Welchner, T., Wetterauer, U.: Different expression of Fas and Fas ligand in tumor infiltrating and perihperal lymphocytes of patients with renal cell carcinomas. Anticancer Research 2003; 23:433–8.
12. Elsässer-Beile, U., Grussenmeyer, T., Gierschner, D., et al.: Semiquantitative analysis of Th1 and Th2 cytokine expression in CD3+, CD4+, and CD8+ renal-cell-carcinoma-infiltrating lymphocytes. Cancer Immunol. Immunother. 1999; 48:204–8. <>
13. Hayakawa, K., Morita, T., Augustus, L.B., et al.: Human renal cell carcinoma cells are able to activate natural killer cells. Int. J. Cancer 1992; 51:290. <>
14. Igarashi, T., Takahashi, H., Tobe, T., et al.: Effect of tumor-infiltrating lymphocyte subsets on prognosis and susceptibility to interferon therapy in patients with renal cell carcinoma. Urol. Int. 2002; 69:51–56. <>
15. Koo, A.S., Tso, C.L., Shimabukuro, T., et al.: Autologous tumor-specific cytotoxicity of tumor-infiltrating lymphocytes derived from human renal cell carcinoma. J. Immunother. 1991; 10:347–54. <>
16. Kowalczyk, D., Skorupski, W., Kwias, Z., Nowak, J.: Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma. Br. J. Urol. 1997; 80:543–7. <>
17. Kronke, M., Leonard, W.J., Depper, J.M., Greene, W.C.: Sequential expression of genes involved in human T lymphocyte growth and differentiation. J. Exp. Med. 1985; 161:1593–8. <> <PubMed>
18. Lucivero, G., Dalla Mora, L., Bresciano, E., et al.: Functional characteristics of cord blood T lymphocytes after lectin and anti-CD3 stimulation. Differences in the way T cells express activation molecules and proliferate. Int. J. Clin. Res. 1996; 26:255. <>
19. Malinowski, K., Kono, K., Takayama, T., et al.: Inhibition of lymphocyte proliferative responses by renal cell carcinoma extract. Transplant. Proc. 1997; 29:839. <>
20. Martel, C.L., Lara, P.N.: Renal cell carcinoma: current status and future directions. Crit. Rev. Oncol. Hematol. 2003; 45:177–190. <>
21. Mitropoulos, D., Kooi, S., Rodriguez-Villanueva, J., Platsoucas, C.D.: Characterization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derivied T cell lines from patients with renal cell carcinoma. Clin. Exp. Immunol. 1994; 97:321–7. <> <PubMed>
22. Netea, M.G., van der Meer, J.W.M., Sutmuller, R.P., et al.: From the Th1/Th2 paradigm towards a toll-like receptor/T-helper bias. Antimicrob. Agents Chemother. 2005; 49(10):3991–6. <> <PubMed>
23. Panelli, M.C., Nagorsen, D., Wang, E., et al.: Mechanism of immune response during immunotherapy. Yonsei Med. J. 2004; 45(Suppl.):15–17. <>
24. Reed, J.C., Alpers, J.D., Nowell, P.C., Hoover, R.G.: Sequential expression of protooncogenes during lecitin-stimulated mitogenesis of normal human lymphocytes. Proc. Natl. Acad. Sci. USA 1986; 83:3982–6. <> <PubMed>
25. Rodriguez, M.A., De Sanctis, J.B., Blasini, A.M., et al.: Human IFN-gamma upregulates IL-2 receptors in mitogen-activated T lymphocytes. Immunol. 1990; 69:554.
26. Santin, A.D., Ravaggi, A., Bellone, S., et al.: Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix. Gynecol. Oncol. 2001; 81:424–32. <>
27. Shabtai, M., Ye, H., Frischer, Z., et al.: Increased expression of activation markers in renal cell carcinoma infiltrating lymphocytes. J. Urol. 2002; 168:2216–19. <>
28. Schoof, D.D., Terashima, Y., Peoples, G.E., et al.: CD4+ T cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells. Cellular Immunol. 1993; 150:114–23. <>
29. van den Hove, L.E., van Gool, S.W., van Poppel, H., et al.: Identification of an enriched CD4+ CD8alpha++ CD8beta+ T-cell subset among tumor-infiltrating lymphocytes in human renal cell carcinoma. Int. J. Cancer 1997; 71:178. <<178::AID-IJC9>3.0.CO;2-Y>
30. van den Hove, L.E., van Gool, S.W., van Poppel, H., et al.: Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating lymphocytes in human renal cell carcinoma. Clin. Exp. Immunol. 1997; 109:501–9. <> <PubMed>
31. Whiteside, T.L., Herberman, R.B.: The role of natural killer cells in immune surveillance of cancer. Curr. Opinion Immunol. 1995; 7:704–10. <>
32. Whitford, P., Mallon, E.A., George, W.D., Campbell, A.M.: Flow cytometric analysis of tumour infiltrating lymphocytes in breast cancer. Br. J. Cancer 1990; 62:971–5. <> <PubMed>
33. Zeromski, J., Dworacki, G., Kruk-Zagajewska, A., et al.: Assessment of immunophenotype of potentially cytotoxic tumor infiltrating cells in laryngeal carcinoma. Arch. Immunol. Ther. Exp. 1993; 41:57–62.
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal